NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Net Sales | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr | ₹1,915 Cr |
What is the latest Revenue of NATCO PHARMA ?
Year | Revenue |
---|---|
Mar2024 | ₹3,999 Cr |
Mar2023 | ₹2,707 Cr |
Mar2022 | ₹1,945 Cr |
Mar2021 | ₹2,052 Cr |
Mar2020 | ₹1,915 Cr |
How is Revenue of NATCO PHARMA Trending?
Years | Revenue | % Change | |
---|---|---|---|
Mar2024 | ₹3,999 Cr | 47.72 | |
Mar2023 | ₹2,707 Cr | 39.20 | |
Mar2022 | ₹1,945 Cr | -5.23 | |
Mar2021 | ₹2,052 Cr | 7.16 | |
Mar2020 | ₹1,915 Cr | - |
Compare Revenue of peers of NATCO PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATCO PHARMA | ₹23,617.9 Cr | 13.5% | 6.7% | 54.6% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹419,764.0 Cr | 0.6% | -2.1% | 16.5% | Stock Analytics | |
DIVIS LABORATORIES | ₹163,010.0 Cr | 4.3% | 6.5% | 63.9% | Stock Analytics | |
CIPLA | ₹118,905.0 Cr | 3.6% | 0.2% | 2.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,523.0 Cr | 3% | -8.4% | 0% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,015.0 Cr | 3.2% | -1% | 27.4% | Stock Analytics |
NATCO PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATCO PHARMA | 13.5% |
6.7% |
54.6% |
SENSEX | 0.5% |
0.3% |
7.9% |
You may also like the below Video Courses